Press release
Alzheimer’s Association Long Island Welcomes New Care Consultant Amy Oster
Alzheimer’s Association Long Island has announced that Amy Oster will join the organization as its Care Consultant. In her new role, Ms. Oster will regularly meet with families of those suffering from Alzheimer’s disease to develop a long-term care plan and discuss available programs and resources. Ms. Oster has been successful in facilitating the support group for caregivers, which has greatly increased in size under her leadership.Before joining Alzheimer’s Association Long Island, Ms. Oster was a Youth Worker for MCCA-New Dawn Therapeutic Group Home, where she helped to develop a dialectical behavioral therapy group for adolescent females, as well as other groups focused on anger management skills. She resides in Lindenhurst.
Ms Oster completed her undergraduate studies at The University of New Haven, where she earned a Bachelor’s Degree in Clinical Psychology. She also has a Master’s degree in Social Work and graduated with distinguished honors from Columbia University. While in graduate school, she performed internships at Yale New Haven Hospital in trauma, medicine and surgery, and at Somers Manor Nursing Home, where she developed art and music therapy groups.
“We are very pleased to welcome Ms. Oster as our Care Consultant,” said Mary Ann Malack-Ragona, Executive Director/CEO, Alzheimer’s Association Long Island. “Her past experience, knowledge and passion for this profession have made her a valuable asset to our organization.”
For more information about Alzheimer’s Association Long Island, please contact Mary Ann Malack-Ragona, Executive Director/CEO at (631) 820-8068 or visit www.alz.org/longisland.
* Photo of Ms. Oster is attached and available upon request.
About Alzheimer’s Association
The Alzheimer's Association is the world’s leading voluntary health organization in Alzheimer’s care, support and research. Our mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer’s. For more information, visit www.alz.org.
Hank Russell, Public Relations Director
The Public Relations and Marketing Group
156 North Ocean Avenue
Patchogue, NY 11772
(631) 207-1057
hrussell@theprmg.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer’s Association Long Island Welcomes New Care Consultant Amy Oster here
News-ID: 217125 • Views: …
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…